2026-04-13T01:04:26Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/102502025-10-04T05:20:26Zcom_2072_378070com_2072_378040col_2072_378092

HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC Yu, Helena A Hayashi, Hidetoshi Goto, Yasushi Reck, Martin Yang, James Chih-Hsin FELIP, ENRIQUETA Anomalies cromosòmiques Pulmons - Càncer - Tractament Immunoglobulines - Ús terapèutic DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Immunoconjugates PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::globulinas séricas::inmunoglobulinas::anticuerpos::inmunoconjugados FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación Antibody–drug conjugate; Non-small-cell lung cancer; Patritumab deruxtecan Conjugat anticossos-fàrmac; Càncer de pulmó de cèl·lules no petites; Patritumab deruxtecan Conjugado anticuerpo-fármaco; Cáncer de pulmón de células no pequeñas; Patritumab deruxtecan Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, and its expression is associated with poor prognosis in some patients. Patritumab deruxtecan (HER3-DXd) is an investigational, potential first-in-class, HER3-directed antibody–drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. In an ongoing phase I study, HER3-DXd demonstrated promising antitumor activity and a tolerable safety profile in patients with EGFR-mutated NSCLC, with or without identified EGFR TKI resistance mechanisms, providing proof of concept of HER3-DXd. HERTHENA-Lung01 is a global, registrational, phase II trial further evaluating HER3-DXd in previously treated advanced EGFR-mutated NSCLC. 2023-09-07T10:39:43Z 2023-09-07T10:39:43Z 2023-06 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Future Oncology;19(19) http://dx.doi.org/10.2217/fon-2022-1250 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Future Medicine Scientia